Hansoh Pharma (03692) announced that a new indication for its innovative drug Ameile® and two new indications for Xinyue® have been successfully added to the new edition of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2026). The new national catalog will officially take effect on January 1, 2027.

In addition, the remaining four indications of the company's innovative drug almonertinib mesylate tablets (trade name: Ameile®), the remaining one indication of inebilizumab injection (trade name: Xinyue®), and flumatinib mesylate tablets (trade name: Haosen Xinfu®) have all been renewed for inclusion in the 2026 national medical insurance catalog. Pegylated loxenatide injection (trade name: Fulimei®) has also been renewed for inclusion in the 2026 national medical insurance catalog, with its medical insurance payment scope expanded.

Pegmolesatide injection (trade name: Shengluolai®) and tenofovir amibufenamide tablets (trade name: Hengmu®) are currently still within the agreement period of the national medical insurance catalog, with the agreement valid until December 31, 2027. Morinidazole and sodium chloride injection (trade name: Mailinda®) has been included in Category B of the national medical insurance routine catalog.

All approved indications of the company's marketed innovative drugs have now been included in the medical insurance catalog, which will help further improve the affordability and accessibility of each innovative drug for patients.